Zenas BioPharma, Inc. (ZBIO)Healthcare | Biotechnology | Waltham, United States | NasdaqGS
31.27 USD
-1.35
(-4.139%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 30.76 -0.51 (-0.510%) ⇩ (Aug. 28, 2026, 7:43 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:59 a.m. EDT
The investment case for Zenas BioPharma is currently paralyzed by a stark disconnect between optimistic analyst targets and the harsh reality of its financials. While analysts see a path to $47-$59, the company reports massive losses, negative operating margins of nearly 78%, and negligible revenue ($1 million trailing twelve months). The balance sheet shows significant cash burn with no clear profitability horizon yet. The short-term outlook is clouded by intense speculative hedging. The options market is screaming caution, with massive put buying at deep discounts creating a floor that suggests traders expect a crash rather than a rally. This sentiment overrides the 'strong buy' analyst ratings, which often lag behind the immediate risks of biotech development. Long-term, the stock remains a speculative gamble on future drug approvals rather than a value investment. With no dividends and a history of price volatility, it lacks the fundamental stability required for a high rating. Until the company demonstrates sustained revenue growth and a path to profitability, it remains a hold for those willing to tolerate extreme risk, but not a core holding. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.181630 |
| MSTL | 0.195454 |
| AutoARIMA | 0.204927 |
| AutoETS | 0.204939 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 3.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.061 |
| Excess Kurtosis | -0.05 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 120.544 |
| Revenue per Share | 0.019 |
| Market Cap | 2,038,076,160 |
| Forward P/E | -6.71 |
| Website | https://zenasbio.com |
As of Aug. 22, 2026, 2:59 a.m. EDT: Speculators are aggressively positioning for downside protection with heavy put volume and open interest concentrated at strikes significantly below the current price (e.g., $10, $17.50, $20). This creates a 'put wall' suggesting a fear of a sharp decline. Conversely, call activity is sparse and mostly clustered near the money or slightly out-of-the-money, indicating a lack of aggressive bullish conviction despite the 'strong buy' analyst consensus.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8618722 |
| Address1 | 852 Winter Street |
| Address2 | Suite 250 |
| All Time High | 44.6 |
| All Time Low | 5.83 |
| Ask | 40.57 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 888,960 |
| Average Daily Volume3 Month | 853,796 |
| Average Volume | 853,796 |
| Average Volume10Days | 888,960 |
| Bid | 23.04 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 3.902 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 31.27 |
| Current Ratio | 9.933 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 32.38 |
| Day Low | 31.19 |
| Debt To Equity | 120.544 |
| Display Name | Zenas BioPharma |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -273,870,016 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.181 |
| Enterprise To Revenue | 1,692.811 |
| Enterprise Value | 1,692,811,136 |
| Eps Current Year | -5.615 |
| Eps Forward | -4.66 |
| Eps Trailing Twelve Months | -9.63 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 29.214 |
| Fifty Day Average Change | 2.0559998 |
| Fifty Day Average Change Percent | 0.07037721 |
| Fifty Two Week Change Percent | 86.18722 |
| Fifty Two Week High | 44.6 |
| Fifty Two Week High Change | -13.329998 |
| Fifty Two Week High Change Percent | -0.29887888 |
| Fifty Two Week Low | 13.5 |
| Fifty Two Week Low Change | 17.77 |
| Fifty Two Week Low Change Percent | 1.3162963 |
| Fifty Two Week Range | 13.5 - 44.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,726,234,200,000 |
| Float Shares | 47,025,006 |
| Forward Eps | -4.66 |
| Forward P E | -6.710301 |
| Free Cashflow | -211,391,632 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 167 |
| Fullday Change | -1.35 |
| Fullday Change Percent | -4.13856 |
| Fullday Price | 30.76 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -212,472,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16686001 |
| Held Percent Institutions | 0.93151003 |
| Implied Shares Outstanding | 65,176,723 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-09-13 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts. |
| Long Name | Zenas BioPharma, Inc. |
| Market | us_market |
| Market Cap | 2,038,076,160 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1815193886 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -484,384,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,126,064,704 |
| Number Of Analyst Opinions | 8 |
| Open | 32.27 |
| Operating Cashflow | -225,972,000 |
| Operating Margins | -77.659 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 857 271 2954 |
| Post Market Change | -0.5100002 |
| Post Market Change Percent | -1.6309569 |
| Post Market Price | 30.76 |
| Post Market Time | 1,787,960,639 |
| Previous Close | 32.62 |
| Price Eps Current Year | -5.5690117 |
| Price Hint | 2 |
| Price To Book | 8.01384 |
| Price To Sales Trailing12 Months | 2,038.0762 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.783 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -1.35 |
| Regular Market Change Percent | -4.13856 |
| Regular Market Day High | 32.38 |
| Regular Market Day Low | 31.19 |
| Regular Market Day Range | 31.19 - 32.38 |
| Regular Market Open | 32.27 |
| Regular Market Previous Close | 32.62 |
| Regular Market Price | 31.27 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 439,130 |
| Return On Assets | -0.34417 |
| Return On Equity | -1.9903901 |
| Revenue Per Share | 0.019 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 65,176,723 |
| Shares Percent Shares Out | 0.17889999 |
| Shares Short | 11,658,986 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 12,169,907 |
| Short Name | Zenas BioPharma, Inc. |
| Short Percent Of Float | 0.2626 |
| Short Ratio | 16.49 |
| Source Interval | 15 |
| State | MA |
| Symbol | ZBIO |
| Target High Price | 59.0 |
| Target Low Price | 32.0 |
| Target Mean Price | 47.0 |
| Target Median Price | 45.0 |
| Total Cash | 643,126,016 |
| Total Cash Per Share | 9.867 |
| Total Debt | 297,860,992 |
| Total Revenue | 1,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -9.63 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 26.067724 |
| Two Hundred Day Average Change | 5.202276 |
| Two Hundred Day Average Change Percent | 0.19956772 |
| Type Disp | Equity |
| Volume | 439,130 |
| Website | https://zenasbio.com |
| Zip | 2,451 |